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and review of the literature
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Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are
pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous
lupus erythematosus (CCLE). Although B-cell depletion therapy (BCDT) has demonstrated
efficacy in SLE with visceral involvement, its usefulness for patients with predominant skin
manifestations has not been fully established. In this single-centre, retrospective study 14 con-
secutive SLE, one CCLE and two SCLE patients with recalcitrant skin involvement were
treated with 2 rituximab 1g, and 1 cyclophosphamide 750mg.
Six months after BCDT, nine of 17 (53%) patients were in complete (CR) or partial remis-
sion (PR). Relapses occurred in 12 patients (71%) at a mean time of 10 1.8 months after
BCDT. A second cycle of BCDT achieved a more sustained remission in seven of nine patients
(78%) lasting for a mean time of 18.4 2.7 months. Minor adverse events were experienced by
three patients. Mean follow-up was 30 months.
Our own results and the literature review demonstrate that BCDT based on rituximab is
well tolerated and may be effective for cutaneous lesions of lupus erythematosus. Randomized
controlled trials are necessary to further evaluate the value of BCDT for this group of
patients. Lupus (2013) 22, 932–939.
Key words: Cutaneous lupus; discoid lupus; subacute lupus erythematosus; systemic lupus
erythematosus
Introduction
Cutaneous manifestations are present in about 80%
of systemic lupus erythematosus (SLE) patients at
somestageduringthediseasecourse,andmaybeclin-
ically diverse.
1 The wide range of mucocutaneous
manifestations is reﬂected in the new SLICC
(Systemic Lupus International Collaborating
Clinics)classiﬁcationcriteriaforSLE,
2whichinclude
acute cutaneous lupus erythematosus (ACLE), sub-
acute cutaneous lupus erythematosus (SCLE),
chronic cutaneous lupus erythematosus (CCLE),
oral ulcers and nonscarring alopecia.
3 In the absence
of lupus nephritis, the SLICC classiﬁcation criteria
suggest a diagnosis of SLE if  4 SLICC criteria
(includingatleastoneclinicalandoneimmunological
criterion) are present. Patients with cutaneouslesions
whodonotfulﬁlthesecriteriawillratherbediagnosed
as SCLE if psoriasiform or annular lesions in sun-
exposed areas (frequently associated with anti-Ro/
anti-La antibodies) are present, or as CCLE without
SLE. Discoid lupus erythematosus (DLE) represents
the most frequent clinical subtype of CCLE. Other
clinical manifestations are lupus profundus/lupus
panniculitis, lupus tumidus and chilblain lupus. Less
than 10% of CCLE patients evolve into SLE during
the disease course.
4
First-line therapy for cutaneous lupus erythema-
tosus consists of antimalarials, and oral or topical
corticosteroids.
4 In severe cases or patients with
SLE additional immunosuppressive drugs (e.g.
azathioprine, mycophenolate mofetil, or cyclophos-
phamide) areadded. To date,there is noreliable evi-
dence to conﬁrm the optimal therapeutic regimen.
5
Treatment-associated complications such as
osteopaenia due to corticosteroids or infections
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festations of lupus erythematosus prove to be extre-
mely refractory to conventional therapy.
6
Therefore, the anti-CD20 monoclonal antibody
rituximab (RTX) has been used as an oﬀ-label
therapeutic option in patients with intolerance or
resistance to standard therapy.
CD20-positive B-cells play an important role in
the pathogenesis of SLE and probably SCLE:
7 in
addition to their role as antigen-presenting cells,
B-cells produce pathogenic autoantibodies, secrete
cytokines, and therefore enhance inﬂammation.
8
We and others have reported that B-cell depletion
therapy (BCDT) based on RTX is eﬀective
against SLE.
9–11 Unfortunately, two recently com-
pleted randomized controlled clinical trials
(EXPLORER, LUNAR) failed to conﬁrm the posi-
tiveeﬀectsofRTX,probablybecauseofissuesinthe
study design with regard to concomitant thera-
pies.
12,13 In case reports and observational studies,
RTX was eﬀective over all organ systems including
the mucocutaneous system.
9 However, the eﬃcacy
ofthisbiologicwithregardtodiﬀerentclinicalmani-
festations of cutaneous involvement in lupus erythe-
matosus has not yet been investigated in detail and
there are very few data on long-term outcomes cur-
rently available.
Here, we report the long-term clinical eﬃcacyand
immunological follow-up of 17 consecutive lupus
erythematosus patients with predominant and ther-
apy-refractory skin involvement necessitating
BCDT from 2007 to 2011 at University College
London Hospital (UCLH). Furthermore, we
reviewed all previously published case reports and
three observational studies ontheuseof RTX-based
BCDT for cutaneous manifestations of lupus
erythematosus.
Patients and methods
Patients and healthy control subjects
Consecutive patients were retrospectively selected
from our well-characterized lupus erythematosus
patient cohort attending UCLH. Inclusion criteria
were i) treatment with RTX-based BCDT between
2007 and 2011, and ii) active and severe cutaneous
lesions before BCDTreﬂected byanAorBscorefor
the mucocutaneous component of the British Isles
Lupus Assessment (BILAG) score in all SLE
patients.
14 The BILAG score is an ordinal scale
index that assesses all organ systems including the
mucocutaneous system. Disease activity is categor-
ized into ﬁve diﬀerent levels from A (very active) to
E (no current or previous activity in this organ
system).
At least four of the SLICC classiﬁcation criteria
2
and of the revised American College of
Rheumatology (ACR) criteria
15 were fulﬁlled by
14 SLE patients included in this study. To identify
the clinical subtype of cutaneous involvement and
to assess the clinical eﬃcacy of BCDT, all patients
were examined by the same dermatologist before
and after BCDT. Cutaneous manifestations of the
SLE patients were classiﬁed as ACLE in three
patients, SCLE in one, CCLE in seven (DLE in
six and/or lupus profundus in two), and non-
speciﬁc SLE-associated lesions (vasculitis or urti-
caria) in addition to oral ulcers in three patients.
Furthermore, two SCLE patients and one patient
with DLE and rheumatoid arthritis were assessed.
All SLE patients had a positive antinuclear antibo-
dies (ANA) titre ( 1:80 by immunoﬂuorescence),
and eight of 14 (57%) had anti-double-stranded
DNA (anti-dsDNA) antibodies by enzyme-
linked immunosorbent assay (ELISA) (Shield
Diagnostics, Dundee, UK; normal <50IU/ml).
Both SCLE patients and the DLE patient had posi-
tive ANA and anti-Ro antibodies, but not anti-
dsDNA antibodies. Demographic and clinical
data of the patients and previously failed treat-
ments are presented in Table 1.
All17patientsreceivedacombinationof1gRTX
and 100mg methylprednisolone intravenously (i.v.)
on two occasions two weeks apart, and 750mg
cyclophosphamide i.v. the day after the ﬁrst RTX
infusion. In the majority of patients (12/17)
immunosuppressive drugs were withdrawn at the
ﬁrst cycle of BCDT to reduce the risk of infectious
complications, and only hydroxychloroquine (at a
stable dose) and prednisolone (in tapering doses)
were continued. In patients no. 4, 5, 6, 15 and 17
BCDT was added to stable immunosuppressive
therapy with azathioprine, mycophenolate mofetil
or methotrexate. Patients were followed up in the
lupus clinic every one to three months, and at each
visit the BILAG activity index and the level of anti-
dsDNA antibodies and C3 (laser nephelometry,
normal 0.9–1.9mg/l) were used to help assess the
disease activity of SLE patients. CD19 counts were
monitored to assess depletion and the time to B-cell
repopulation. Clinical and serological datawere col-
lected prospectively. The study was approved by the
UCLH ethics committee.
Outcome measures
The response to BCDT was assessed at six months
after the last RTX infusion. Complete remission
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Lupus(CR) was deﬁned as absence of skin lesions
(reﬂected by a mucocutaneous BILAG D for
the group of SLE patients) for at least two
months and treatment with 5mg prednisol-
one hydroxychloroquine. Partial remission (PR)
was deﬁned as improvement of cutaneous manifest-
ations (to BILAG C) of at least 50% or complete
clearance of skin lesions (BILAG D) with continu-
ation of immunosuppressants after BCDT. Stable
disease (SD) was deﬁned as no or only minor
improvement of cutaneous lesions (mucocutaneous
BILAG A or B). The eﬀect of BCDT on organ
systems other than the mucocutaneous system was
not investigated in this study.
Statistical procedures
Descriptive statistics are reported as frequency or
percentage for categorical variables and as
mean SE for continuous variables. Statistical
analyses were performed with GraphPad Prism
(Chicago, IL, USA), using the nonparametrical
Mann-Whitney U test. P values of <0.05 were con-
sidered to be statistically signiﬁcant.
Results
Efficacy and safety of BCDT in our patients
In this study, one man and 16 women of diﬀerent
ethnicities (seven Whites, eight Afro-Caribbeans
and two Asians) were included. The mean age
was 43 3.6 years, and the mean disease duration
prior to BCDT was 11 1.8 years. All patients were
refractory to previous treatments including oral
prednisolone and antimalarials, topical steroids
and/or topical tacrolimus for at least six months
with the exception of patient 16, who did not tol-
erate antimalarials. In addition, 12/17 patients
(71%) had received classical immunosuppressive
agents without improvement.
B-cell depletion deﬁned as CD19 absolute num-
bers <0.005 10
9/l was achieved by all patients fol-
lowing BCDT. Mean time to B-cell repopulation
was 7.7 1.2 months (range three to 18 months).
Although 12 patients (71%) demonstrated a fast
improvement of at least 50% of their skin lesions
within three months after the ﬁrst BCDT treat-
ment, it was, however, only of short duration in
some patients. Two patients (no. 8 and 11) demon-
strated a slower response, with CR or PR occurring
four and ﬁve months after BCDT, respectively. Six
months after the ﬁrst BCDT, CR was observed in
ﬁve of 17 patients (29.4%) and PR in four of 17
patients (23.5%). Eight patients had SD (47.1%).
These results are shown as changes in the mucocu-
taneous BILAG score in Figure 1 (a) for the SLE
patients. Of the three patients without SLE and
therefore lacking BILAG assessment (patients no.
15–17), both patients with SCLE achieved PR while
the patient with DLE and rheumatoid arthritis
remained active (SD).
With regard to the subtype of cutaneous lesions,
two of three ACLE patients (66.6%), two of three
SCLE patients (66.6%) and two of three SLE
patients with non-speciﬁc lesions (66.6%) were in
CR or PR six months after the ﬁrst cycle of BCDT,
in contrast to only three of eight (37.5%) patients
with CCLE lesions. We have not observed any
transition from one type of cutaneous manifest-
ation to another type following BCDT.
Eight of 17 (47%) patients had elevated dsDNA
antibodies prior to BCDT (mean 476.9 220.6IU/
ml). There was a trend to a reduction of dsDNA
levels within six months to 242.8IU/ml 138.9
which did not reach statistical signiﬁcance
(p¼0.38). CR or PR was obtained by six of eight
(75%) patients with anti-dsDNA antibodies com-
pared to ﬁve of nine (56%) of anti-dsDNA negative
patients.
Low complement C3 was detectable in 10/17
(59%) patients (mean 0.71g/l 0.05) before
treatment, but improved signiﬁcantly (mean
0.95g/l 0.04) after six months (p¼0.001).
Adverse events were experienced by two patients
(urticaria post-infusion or recurrent chest infections
after BCDT), but no serious complications
occurred.
Although six patients (35%) maintained PR or
CR for more than 12 months (patients no. 3 and 7
with ACLE, patient no. 15 with SCLE, patients no.
10 and 14 with DLE, and patient no. 11 with cuta-
neous vasculitis), relapses were frequent and
occurred in 12 patients (71%) at a mean time of
10 1.8 months after the ﬁrst cycle of BCDT
(range three to 23 months) (Table 1). The time
interval between the ﬁrst cycle of BCDT and occur-
rence of a relapse was not diﬀerent between SLE
patients with CCLE and those with other subtypes
of cutaneous lupus erythematosus (ACLE, SCLE
and non-speciﬁc lesions) (p¼0.8).
Of patients with a ﬂare of their cutaneous lupus
erythematosus or with SD after the ﬁrst BCDT,
eight SLE patients and one SCLE patient received
a second course of BCDT resulting in CR in three
of nine patients (33.3%), and in PR in four of nine
patients (44.4%), while patients no. 4 and 5 again
failed to respond (Figure 1(b)). Of the seven
responding patients, ﬁve experienced another ﬂare
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Lupus(71%) occurring at a mean time of 18.4 2.7
months (range nine to 24) after the second cycle
of BCDT. One patient (no. 1) experienced an aller-
gic reaction during the RTX infusion at this time,
while there were no side eﬀects in the remaining
patients. Mean time to B-cell repopulation after
the second cycle of BCDT was 7.0 1.3 months
(range three to 13 months) and mean follow-up
29.9 3.1 months (six to 60).
Discussion
Rituximab is an anti-CD20 monoclonal antibody
that is United States Food and Drug
Administration (FDA) approved for treatment of
B-cell lymphomas and rheumatoid arthritis. In
dermatology, intravenous administration of RTX
has been used oﬀ-label with promising results in
several autoimmune disorders, e.g. pemphigus dis-
eases, graft-versus-host disease and vasculitis.
16,17
In the literature, seven cases of SLE patients with
cutaneous manifestations (three ACLE, two SCLE,
one CCLE and one patient with non-speciﬁc
lesions) and three SCLE patients treated with
RTX-based BCDT due to otherwise refractory
cutaneous manifestations are published (Table 2).
These reports suggested that BCDT may be bene-
ﬁcial for patients with severe cutaneous lesions of
lupus erythematosus if ﬁrst-line treatment was not
suﬃcient or tolerated:
18–24 of the 10 patients, eight
(80%) achieved CR, two patients PR. Three
patients (30%) experienced a relapse within one
year, but their skin lesions were cleared by another
cycle of BCDT. Serious side eﬀects were not
reported in any of these patients.
Although these reports are encouraging, the
rather short mean follow-up of these patients
(14.3 5.2 months) and the fact that usually only
successfully treated cases are published, prompted
us to investigate retrospectively the long-term out-
come of consecutive patients treated with BCDT at
UCLH for severe cutaneous manifestations of
lupus erythematosus between 2007 and 2011. Our
results indicate that BCDT based on 2 1g RTX
and a single dose of 750mg cyclophosphamide led
to a signiﬁcant clinical improvement in 53% of SLE
patients who were previously refractory to
immunosuppressive treatment including
Figure 1 Clinical response to BCDT treatment in lupus erythematosus patients with severe cutaneous manifestations treated at
UCLH. (a) Bars represent the mucocutaneous BILAG score at zero, three and six months after BCDT in 14 SLE patients.
Numbers on the x-axis refer to the patients as described in Table 1. BILAG A indicates a severe mucocutaneous involvement,
BILAG B moderate, BILAG C mild and BILAG D inactive mucocutaneous disease. (b) BILAG scores of eight SLE patients who
relapsed and received a second cycle of BCDT (mucocutaneous score at zero, three and six months after BCDT).
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Lupusantimalarials, high-dose oral corticosteroids and
immunosuppressive drugs (Table 1).
A good clinical response to BCDT was previ-
ously reported in three open-label studies
(Table 2): in childhood-onset SLE with skin
lesions, CR was achieved by three of six (50%)
children after one cycle of BCDT.
25 Two retro-
spective studies reported CR in nine of 16 (56%)
and 29/61 (48%) of adult SLE patients with muco-
cutaneous lesions after a ﬁrst cycle of BCDT,
respectively.
9,11
Although we used a slightly more aggressive
regimen including 100mg methylprednisolone
twice and a single administration of 750mg
cyclophosphamide to achieve maximal B-cell
depletion, our remission rate (CR in 29% of
patients after one cycle of BCDT) is lower
than reported in the open-label study of SLE
patients from the French AutoImmunity and
Rituximab Registry
11 and in our own retrospect-
ive study
9 including some SLE patients with
cutaneous lesions. The higher response rates in
these studies may be explained by a shorter
follow-up (six months 3 months in the study
by Terrier et al.
11) and/or diﬀerences in the sub-
type of cutaneous manifestations of the included
patients. While the clinical subtypes of the muco-
cutaneous lesions were not speciﬁed in these pre-
viously published studies, we here demonstrate
that BCDT was beneﬁcial in particular in
patients with ACLE, SCLE or non-speciﬁc cuta-
neous lesions. In contrast, less than a third of
CCLE patients, whether or not in the context of
SLE, achieved complete remission after BCDT.
These diﬀerences in response rates to BCDT
depending on the type of cutaneous manifest-
ations are potentially reﬂected in the fact that
only one of the reviewed case reports
20 demon-
strated remission in a patient with CCLE (lupus
erythematosus profundus) in the context of SLE
while the remaining cases featured patients with
ACLE, SCLE or non-speciﬁc skin lesions. It is
conceivable that diﬀerent mechanisms play a role
in the pathogenesis of CCLE compared to
ACLE, SCLE or non-speciﬁc cutaneous lesions
in SLE. CCLE patients without SLE present
with ANA in only 10%–30% of cases
3 compared
to >80% in SCLE and SLE, which suggests
that B-cells are not playing an essential role in
the development of DLE lesions. In contrast,
skin homing of CCR4 expressing CD8
þ cyto-
toxic T cells has been implicated to be of
major importance in the pathogenesis, particu-
larly of the disseminated and scarring type of
DLE.
26 Furthermore, ACLE and non-speciﬁc
cutaneous lesions are manifestations that usually
reﬂect acuteness of SLE. Most immunosuppres-
sive treatments used for cutaneous lupus erythe-
matosus are more eﬃcient in treating acute
disease than long-standing CCLE lesions,
4 and
this observation seems to hold true also for
BCDT. In contrast, immunomodulatory therapies
such as thalidomide were shown to achieve
higher rates of remission in DLE compared to
ACLE.
27
Despite the fact that antibody-producing plasma
cells are CD20 negative, the clinical response to
BCDT treatment commonly parallels a reduction
– though often not a normalization – of anti-
dsDNA autoantibody levels presumably by pre-
venting formation of new plasma cells.
9 In this
study, only 47% of patients initially demonstrated
elevated anti-dsDNA antibodies, which improved
after BCDT in all patients. Similarly, 59% of
patients had low C3 levels prior to BCDT and C3
levels normalized in all but one patient after BCDT,
in line with previous studies.
28
In our patients, B-cell repopulation occurred at a
mean of 7.7 and 7.0 months after the ﬁrst and
second cycle of BCDT, respectively, indicating
that regeneration of the peripheral B cell popula-
tion is not impaired by repeated treatments.
Furthermore, the tolerability proﬁle of RTX did
not change after a second cycle of RTX, a ﬁnding
that has also been observed in patients with
rheumatoid arthritis.
29 Noteworthy, despite B-cell
repopulation at approximately seven months,
patients who achieved remission after BCDT usu-
ally remained disease free for 10 months after the
ﬁrst cycle of BCDT, and for even 18 months after
repeated BCDT. Nearly all of these patients
received maintenance treatment with only antimal-
arials and low-dose prednisolone.
This single-centre study evaluated only a small
number of patients, and a quantitative scoring
system for severity of skin lesions such as the
Revised Cutaneous Lupus Activity and Severity
Index (RCLASI)
30 was not used because it is too
detailed to be applied retrospectively. Despite these
limitations, our analysis demonstrates that some
lupus erythematosus patients with active mucocu-
taneous lesions, in particular those with ACLE,
SCLE or vasculitis, achieve a long-lasting clinical
remission and beneﬁt from BCDT, even if they
were previously resistant to conventional therapy.
Moreover, BCDT was well tolerated both at short
and long term. Randomized controlled trials
should be conducted to further evaluate the value
of BCDT for the treatment of cutaneous manifest-
ations of lupus erythematosus.
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